Warning Letter — Macau-Union Pharmaceutical Limited
The FDA issued a Warning Letter to Macau-Union Pharmaceutical Limited following an evaluation by the Center for Drug Evaluation and Research (CDER). The letter details regulatory non-compliance at the firm's manufacturing facility.
This affects Macau-Union Pharmaceutical Limited, its quality and manufacturing departments, and any pharmaceutical distributors or partners relying on their supply chain for products regulated by CDER.
A Warning Letter from CDER signifies significant deviations from standard regulatory requirements, which may lead to import alerts or the withholding of product approvals. For compliance professionals, this underscores the FDA's continued oversight of international manufacturing sites and the potential for operational disruptions if CGMP standards are not strictly maintained.
Regulatory and QA teams should immediately review the compliance status of foreign manufacturing partners and ensure all site registrations are current. Verify that current good manufacturing practice (CGMP) documentation is complete and accessible for inspection to avoid importation restrictions or regulatory enforcement.
FDA Warning Letter issued to: Macau-Union Pharmaceutical Limited. 05/29/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/macau-union-pharmaceutical-limited-724506-05292026
Open in openFDA / FDA.gov